Mumbai-based pharmaceutical major Sun Pharmaceutical Industries Ltd reported a robust set of third-quarter results for FY26, beating street expectations with a 16 % year-on-year increase in consolidated net profit to ₹3,369 crore for the quarter ended December 31, 2025, according to company filings.
Revenue from operations also grew strongly, rising about 13 %-15 % YoY to over ₹15,500 crore, driven by steady domestic demand and growth in global branded and innovative medicines. Sun Pharma’s earnings before interest, tax, depreciation and amortisation (EBITDA) jumped more than 23 % YoY, while margins expanded year-on-year, reflecting improved operational efficiency.
The company’s board also approved an interim dividend of ₹11 per equity share, with the record date set for early February. Management highlighted strong performance across key segments including branded businesses in India, emerging markets and innovative medicines, which helped offset softer generic sales in certain markets.
Sun Pharma’s results underscored broad-based growth and a balanced revenue mix as the drugmaker continues to invest in innovation and pipeline expansion.
Mumbai-based pharma major Sun Pharmaceutical Industries Ltd ne FY26 ke third quarter (Q3) mein strong financial performance dikhate hue Street expectations ko beat kiya hai. Company ka consolidated net profit 16% year-on-year badhkar ₹3,369 crore par pahunch gaya, jo analysts ke estimates se behtar raha.
Quarter ke dauraan revenue from operations mein bhi double-digit growth dekhi gayi, jo lagbhag 13–15% YoY rahi. Is growth ko mainly domestic formulations business, global branded portfolio aur speciality products se support mila. Company ke EBITDA aur margins mein bhi improvement dekha gaya, jo better operational efficiency ko dikhata hai.
Sun Pharma management ne kaha ki India business aur emerging markets mein steady demand bani rahi, jisne kuch international markets mein generic segment ke pressure ko offset kiya. Innovation aur speciality medicines par continued focus ka bhi results par positive impact pada.
Strong Q3 performance ke saath, company ke board ne ₹11 per share interim dividend announce kiya hai, jisse investors ka confidence aur majboot hua hai.
Overall, Sun Pharma ke Q3 results yeh signal dete hain ki challenging global environment ke bawajood company ki growth momentum aur earnings visibility strong bani hui hai.